NDAINTRAVENOUSPOWDER
Approved
Sep 2009
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 22m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIBATIV (telavancin hydrochloride) is a lipoglycopeptide antibiotic administered intravenously for the treatment of complicated skin and skin structure infections and hospital-acquired/ventilator-associated bacterial pneumonia caused by susceptible gram-positive pathogens. It is a semi-synthetic derivative of vancomycin with enhanced tissue penetration and gram-positive coverage.
$0.782MPart D
LOE ApproachingDeclining
6mo to LOELate-stage product with minimal Part D volume and declining claims suggests small, consolidating commercial footprint with limited growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
VIBATIV Pregnancy Registry
Started Nov 2009
0Pregnancy
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Worked on VIBATIV at Cumberland Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.